血浆与他克莫司全血浓度与肾移植结局:ALLEGRO试验事后分析
该事后分析基于ALLEGRO随机试验的295例肾移植受者,比较血浆他克莫司浓度(PTC)与全血浓度(WBTC)与eGFR、小动脉玻璃样变等结局的关联。结果显示早期和晚期平均PTC与eGFR负相关,而WBTC无此关联;晚期PTC与小动脉玻璃样变风险相关,WBTC无显著关联。
要点
- 血浆他克莫司浓度与后期eGFR负相关,全血浓度无此关联。
- 晚期血浆他克莫司浓度与小动脉玻璃样变风险相关,全血浓度无显著关联。
- PTC与WBTC均与感染和活检证实的排斥反应无显著关联。
核心结论
- 血浆他克莫司浓度较全血浓度更能反映他克莫司相关的肾功能下降和小动脉玻璃样变风险,但需更大样本研究验证。
研究设计与样本
- ALLEGRO随机试验的事后分析,纳入295例肾移植受者,随机分为标准三联免疫抑制、低他克莫司暴露或撤除泼尼松龙组。
- PTC采用液相色谱-串联质谱法测定。
主要发现
- 移植后第一个月平均PTC为0.31±0.17 ng/ml,与4周时eGFR负相关(标准化β=-0.17 [-0.29至-0.05],P=0.006),而WBTC无显著关联(标准化β=0.09 [-0.03至0.22],P=0.15),两者差异有统计学意义(P=0.004)。
- 晚期(6.5-24个月)平均PTC为0.15±0.07 ng/ml,与2年时eGFR负相关(标准化β=-0.19 [-0.35至-0.03],P=0.02),而WBTC无显著关联(标准化β=0.04 [-0.13至0.20],P=0.66),差异有统计学意义(P=0.02)。
- 2年时71例方案活检中10例(14%)显示中重度小动脉玻璃样变;晚期平均PTC与小动脉玻璃样变风险显著相关(OR=1.96 [1.07-3.80],P=0.03),WBTC无显著关联(OR=1.65 [0.83-3.53],P=0.17)。
- 单变量分析中PTC和WBTC均与感染风险无显著关联;22例(7%)发生活检证实的排斥反应,PTC和WBTC均与排斥无关联。
临床怎么用
- 在肾移植受者中,血浆他克莫司浓度可能比全血浓度更敏感地提示他克莫司相关肾毒性(eGFR下降和小动脉玻璃样变),但当前证据尚不足以支持常规替换监测方法。
局限性
- 小动脉玻璃样变事件数有限,需更大样本研究验证。
- 本研究为事后分析,结论需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Repeated measurements of plasma tacrolimus concentrations were obtained retrospectively from 295 kidney transplant recipients. Plasma tacrolimus concentration was negatively associated with later eGFR, whereas whole blood concentration was not. Plasma tacrolimus concentration was associated with arteriolar hyalinosis in protocol biopsies, whereas whole blood concentration was not. BACKGROUND: Tacrolimus is the cornerstone of immunosuppressive treatment after kidney transplantation. Its application requires therapeutic drug monitoring, which is routinely performed by assessment of whole blood tacrolimus concentrations (WBTC) that largely comprises a pharmacologically inactive fraction. Monitoring tacrolimus exposure using the plasma tacrolimus concentration (PTC) may better reflect the pharmacologic active fraction. We hypothesized that PTC better reflects effectivity and toxicity than WBTC. METHODS: The Amsterdam, LEiden, GROningen trial randomized 295 kidney transplant recipients (KTR) to standard triple immunosuppression, lower tacrolimus exposure, or withdrawal of prednisolone. PTC was measured using liquid chromatography-tandem mass spectrometry. Associations between tacrolimus concentrations and eGFR were analyzed using linear regression, with bootstrap resampling used to compare PTC and WBTC. Associations with biopsy results and rejection were evaluated using logistic regression, and infection risk was assessed with joint modeling. RESULTS: The mean age was 56.5±13.2 years, and 95 (32%) were female. The mean PTC during the first month post-transplantation (0.31±0.17 ng/ml) was negatively associated with eGFR at 4 weeks (st. β =-0.17 [-0.29 to -0.05], P = 0.006), whereas mean WBTC was not (st. β =0.09 [-0.03 to 0.22], P = 0.15), and the difference between these associations was statistically significant ( P = 0.004). Late mean PTC (6.5-24 months; 0.15±0.07 ng/ml) was negatively associated with eGFR at 2 years (st. β =-0.19 [-0.35 to -0.03], P = 0.02), whereas mean WBTC was not (st. β =0.04 [-0.13 to 0.20], P = 0.66), and this difference was also statistically significant ( P = 0.02). At 2 years, 10 (14%) of the 71 protocol biopsies showed moderate-to-severe arteriolar hyalinosis. Although in a limited number of events, late mean PTC was significantly associated with a risk of arteriolar hyalinosis (odds ratio=1.96 [1.07-3.80], P = 0.03), WBTC was not (odds ratio=1.65 [0.83-3.53], P = 0.17). Neither PTC nor WBTC was significantly associated with a risk of infection in univariable analysis. Twenty-two KTR (7%) experienced biopsy-proven rejection; neither PTC nor WBTC was associated with rejection. CONCLUSION: Larger studies are needed to determine whether late PTC is a better marker than WBTC to detect potential tacrolimus-related nephrotoxicity in KTR. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT01560572 .
引用
- Jonker J, van den Born JC, Kremer D, et al. Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation: Post Hoc Analysis of the ALLEGRO Trial. Clin J Am Soc Nephrol. 2026. PMID: 42726515. doi:10.2215/CJN.0000001214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。